BILL ANALYSIS
HR4475
BULLISHMedicare Orthotics and Prosthetics Patient-Centered Care Act
HR4475 (Medicare Orthotics and Prosthetics Patient-Centered Care Act) has been assessed with a bullish outlook for investors. This legislation directly affects $STRR and Zimmer Biomet ($ZBH). The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.
bullish
Market Sentiment
2
Affected Stocks
1
Sectors Impacted
Key Takeaways for Investors
HR4475 is a regulatory bill with $0 authorized funding — its impact is entirely structural, not fiscal.
Bans on drop shipments and expanded practitioner exemptions protect established O&P manufacturers and distributors from low-cost mail-order competition.
ZBH (orthopedic implants and bracing) and STRR (custom O&P fabrication) are positioned to benefit if the bill advances, but passage is uncertain given early-stage status.
Actual stock price action on $ZBH (-13.38% in 7 days) and $STRR (+4.09% in 7 days) is driven by company-specific factors (likely earnings/guidance), not this bill's legislative progress.
Legislative timeline: requires committee hearings, markup, House floor vote, Senate floor vote, and President's signature — realistically 12-24 months if at all.
How HR4475 Affects the Market
Current market action on $ZBH shows severe 7-day weakness (-13.38%) unrelated to this bill — ZBH is trading at $80.07, down from $94.78 on April 16, nearly hitting its 52-week low of $78.83. This decline likely reflects earnings or product-line concerns, not legislative risk. $STRR is flat (+4.09% 7-day, -6.47% 30-day) at $9.68, reflecting its micro-cap volatility. Investors should note: this bill is not causing current price action. A legislative catalyst would require actual committee advancement. For pure-play O&P exposure, $STRR offers higher sensitivity per market cap but lower liquidity. $ZBH offers diversified orthopedics exposure with lower legislative beta but broader institutional coverage.
Bill Details
| Metric | Value |
|---|---|
| Bill Number | HR4475 |
| Market Sentiment | bullish |
| Event Date | |
| Affected Sectors | Healthcare |
| Affected Stocks | $STRR, Zimmer Biomet ($ZBH) |
| Source | View on Congress.gov → |
Summary
HR4475 is an early-stage bill that bans Medicare payment for drop-shipped orthotics and prosthetics, forcing patient fitting by qualified practitioners. This protects established providers like $ZBH and $STRR from low-cost mail-order competition but faces a long legislative path with zero direct federal funding attached.